Active Thyroid Cancer Specific Trials

For available solid tumor basket trials please e-mail us at

1) Active Surveillance of Papillary Thyroid Microcarcinoma
2) RIFTOS MKI (observational) Radioactive Iodine refractory asymptomatic patients in differentiated Thyroid cancer: an Observational Study to assess the use of MultiKinase Inhibitors
3) A Multicenter, Randomized, Double-blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
4) Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
5) An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)